Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial ...

PDS01ADC is a tumor-targeted IL-12 immunocytokine designed to activate the immune system directly within the tumor ...

PDS Biotech’s stock has jumped nearly 25% after its tumour-targeting fused antibody drug conjugate (ADC) elicited a 78% ...

Preclinical study provides first direct evidence linking colorectal cancer metastasis to the glucose-fructose blend found in sugar-sweetened beverages Metastasis is the leading cause of death among ...

Here’s some gut-wrenching news. A troubling complication of colorectal cancer, the third-most common cancer in the US, is showing up in young adults at alarming rates. The American Cancer Society ...

The trial focused on patients with microsatellite-stable or mismatch repair-proficient metastatic colorectal cancer with liver metastases ・The treatment delivered an ORR of nearly 78%, compared to 35% ...

Detailed price information for Pds Biotechnology Corp (PDSB-Q) from The Globe and Mail including charting and trades.

After his colon cancer returned in full force, Marine Corps veteran Joe Worthy decided to help other veterans, advocating for ...

These advances, still under investigation, hold the promise of revolutionizing healthcare for future colorectal cancer ...

Colorectal cancer is now the number one cause of cancer death in adults under 50, according to a 2026 report from the American Cancer Society. Here are 20 numbers to know 1. In 2016, 45% of new ...